Key Takeaway: CBeyond has released topline data from its Phase 2a trial, indicating that nimacimab is effective both as a standalone treatment and in combination with semaglutide, a GLP-1 therapeutic. The results highlight significant weight loss, along with favorable tolerability and safety profiles. This data may support further development of nimacimab in obesity management.
Price reaction · baseline $4.75 (2025-10-03 close) · hit pre-market · 1 other SKYE headline(s) in the window, move may be shared
day 0 close
-60%
day 1 · peak
-65.1%
day 3
-63.8%
Market Sentiment Analysis
POSITIVE FACTORS
Nimacimab shows promising results as a monotherapy.
Combination therapy with semaglutide demonstrates weight loss benefits.
Positive tolerability and safety outcomes reported.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+84%
120-day peak, hindsight
Typical move
24.3%
average across 4 past catalysts
Cash runway
~4 mo
High dilution risk
Lead asset
Nimacimab
Phase 2 · Obesity
Full Press Release Details
All
Primers
Perspectives
Progress
Press
CBeyond P2a Data: Nimacimab as Mono and Combination Therapy
Date published:
October 6, 2025 10:50 am PDT
Share
CBeyond Phase 2a topline data highlights nimacimab as monotherapy and in combination with a GLP-1 therapeutic, semaglutide, with weight loss, tolerability and safety outcomes
Related Documents:
P2a Topline Data Conference Call: Slides
P2a Topline Data Conference Call: Transcript
Frequently Asked Questions
What is the focus of the CBeyond P2a trial?
The trial focuses on nimacimab as a monotherapy and in combination with semaglutide.
What were the outcomes of the nimacimab trial?
The trial reported positive weight loss, tolerability, and safety outcomes.